{"success":true,"data":{"pressRelease":{"id":"124483","rtpr_id":"nPn9Y14j6a","ticker":"PINK","exchange":"","all_tickers":["PINK"],"title":"Perimeter Announces Preliminary Second Quarter 2026 Financial Results","author":"PR Newswire","published_at":"2026-08-20T20:30:00.046Z","article_body":"Perimeter Announces Preliminary Second Quarter 2026 Financial Results\n\nPR Newswire\n\nTORONTO and DALLAS, Aug. 20, 2026\n\nResults characterized by continued strong commercial momentum and improved\noperating performance\n\nConference call/webcast today at 5:00 pm ET\n\nTORONTO and DALLAS, Aug. 20, 2026 /PRNewswire/ -- Perimeter Medical Imaging\nAI, Inc. (TSXV: PINK) (OTCQX: PYNKF) (\"Perimeter\" or the \"Company\"), a\ncommercial-stage medical technology company, today reported preliminary\nfinancial results for its second quarter ended June 30, 2026, and provided a\ncorporate update. Unless specified otherwise, all amounts in this press\nrelease are expressed in U.S. dollars and are presented in accordance with\nInternational Financial Reporting Standards as issued by the International\nAccounting Standards Board.\n\n\"The commercial momentum that's been building over the past several quarters\nhas allowed us to execute our transition from selling our legacy FDA\n510(K)-cleared S-Series OCT to launching our next-generation, AI-enabled and\nFDA PMA-approved Claire™ OCT device from a position of strength,\" commented\nAdrian Mendes, Perimeter's Chief Executive Officer. \"And the results of that\nhave thus far exceeded our expectations, with the first two Claire placements\nalready made, and the first Claire commercial deployment by a major cancer\ncare center achieved. We look forward to updating all of our stakeholders as\nwe continue to grow.\"\n\nBusiness Highlights\n\nLegacy S-Series OCT to Commercial Launch of Claire OCT+AI\n\n * While the Company made final preparations ahead of the commercial launch of\nits flagship Claire OCT+AI device in the second quarter, recurring revenue\nfrom its legacy S-Series OCT grew 31% sequentially quarter-over quarter.\n * In April 2026, the Company formally unveiled Claire at the 27th Annual Meeting\nof the American Society of Breast Surgeons (ASBrS) in Seattle, WA.\n * Perimeter achieved the first two commercial placements of the Claire device\n– consisting of legacy replacements of Perimeter S-Series systems by two\ntop-tier hospitals – in May 2026, marking a critical step as the Company\nworks to establish its proprietary technology as a standard of care in\nbreast-conserving surgery.\n * In June 2026, Perimeter was selected to receive a $148,000 contribution from\nthe\nINOVAIT Pilot Fund\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4756831-1&h=1621375381&u=https%3A%2F%2Finovait.ca%2Ffunding%2F&a=INOVAIT+Pilot+Fund)\n\nto help build the next layer of Claire's infrastructure.\n * Last week, Perimeter announced that Intermountain Health, the largest\nnonprofit health system in the Mountain West region, had become the first\nhealth system in the U.S. to commercially deploy Claire for real-time margin\nassessment in breast-conserving surgeries.\nCorporate\n\n * In May 2026, Perimeter closed the final tranche of its previously announced\n\"best efforts\" offering, pursuant to the listed issuer financing exemption\n(Life Offering), bringing the total offering up to the maximum offering size\nof 21,489,000 units at a price of $0.35 per unit (C$7,521,150).\n * In June 2026, the Company closed the final tranche of its previously announced\nnon-brokered private placement (the \"Debenture Offering\") of C$1,000 principal\namount 3.59% convertible debentures of the Company (the \"Convertible\nDebentures\"). Under the first and second tranches of Debenture Offering, the\nCompany issued an aggregate of C$6,040,000 principal amount of Convertible\nDebentures.\nSummary Preliminary Second Quarter 2026 Financial Results(1)\n\nRevenue was approximately $503,000 for the second quarter of 2026, with the\nfull amount coming from recurring revenue, which consisted of the sale of\nS-Series consumables and system leases, as well as from preventative\nmaintenance services and the sale of ESP warranty programs. Second quarter\n2026 revenues were essentially unchanged from $506,000 in Q1-2025, and up 31%\nfrom approximately $385,000 in Q1-2026.\n\nOperating expenses for the three months ended June 30, 2026 were approximately\n$3.1 million, down 28% from $4.3 million in the same period in 2025.\n\nSecond quarter 2026 net loss was approximately $2.6 million, or $0.02 per\ncommon share, a 33% improvement compared to approximately $3.9 million, or\n$0.04 per common share, in the three months ended June 30, 2025.\n\nCash used in operating activities in the six months ended June 30, 2026, was\napproximately $5.1 million, a 23% decrease from the comparable period in 2025.\n\nAs of June 30, 2026, cash was approximately $6.4 million.\n\n(1) These preliminary financial results are subject to customary financial\nstatement procedures by the Company and its auditors. Actual results could be\naffected by subsequent events or determinations. While the Company believes\nthere is a reasonable basis for these preliminary financial results, the\nresults involve known and unknown risks and uncertainties that may cause\nactual results to differ materially. Preliminary fiscal results represent\nforward-looking information. See \"Forward-Looking Statements\" and \"Financial\nOutlook\".\n\nConference Call\n\nThe Company will host a conference call and live audio webcast today at 5:00\npm Eastern Time to discuss its second quarter 2026 results and provide a\ncorporate update. To participate in the call, please dial 1-800-717-1738 or\n1-646-307-1865. The conference call will also be broadcast live online through\na listen-only webcast\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4756831-1&h=2503541369&u=https%3A%2F%2Fviavid.webcasts.com%2Fstarthere.jsp%3Fei%3D1771430%26tp_key%3D1168c24061&a=listen-only+webcast)\n, which will be posted on the Investors section of the Company's website\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4756831-1&h=3745814786&u=https%3A%2F%2Fir.perimetermed.com%2F&a=Company%27s+website)\n and archived for approximately 90 days.\n\nAbout Perimeter Medical Imaging AI, Inc.\n\nBased in Toronto, Canada and Dallas, Texas, Perimeter Medical Imaging AI\n(TSX-V: PINK) (OTCQX: PYNKF) is a medical technology company driven to\ntransform cancer surgery with ultra-high-resolution, real-time, advanced\nimaging tools to address areas of high unmet medical need. Claire™, recently\napproved by the U.S. Food and Drug Administration (FDA), is our\nnext-generation AI-enabled device. The Company's ticker symbol \"PINK\" is a\nreference to the pink ribbons used during Breast Cancer Awareness Month.\n\nIndications for Use: The Claire OCT System is an adjunctive three-dimensional\nimaging tool which provides volumetric cross-sectional, real-time depth\nvisualization, coupled with an artificial intelligence computer-aided\ndetection algorithm which identifies and marks focal areas suspicious for\nbreast cancer. It is used concurrently with physician interpretation of the\nimages. The Claire OCT System is intended for use in conjunction with other\nstandard methods for evaluation of the margins of excised lumpectomy tissue\nduring surgical procedures in patients with a biopsy-confirmed diagnosis of\nbreast cancer.\n\nThe Claire OCT System should not be used to replace standard tissue\nhistopathology assessment and should not be used for diagnosis. The device is\nnot intended for use in any of the following individuals: under the age of 18,\nmale, have metastatic cancer (Stage IV), have lobular carcinoma as their\nprimary diagnosis, have had previous ipsilateral breast surgery for benign or\nmalignant disease within two years (including implants and breast\naugmentation), patients with multi-centric disease (histologically diagnosed\ncancer in two different quadrants of the breast), unless resected in a single\nspecimen, patients with bilateral disease (diagnosed cancer in both breasts),\npatients who are currently lactating, patients who are currently pregnant, or\nconcurrent use in surgeries with cryo-assisted localization. Refer to\nprescriber labeling for full safety information.\n\nNeither the TSX Venture Exchange nor its Regulation Services Provider (as that\nterm is defined in policies of the TSX Venture Exchange) accepts\nresponsibility for the adequacy or accuracy of this release.\n\nForward-Looking Statements\n\nThis news release contains statements that constitute \"forward-looking\ninformation\" within the meaning of applicable Canadian securities legislation.\nIn this news release, words such as \"may,\" \"would,\" \"could,\" \"will,\" \"likely,\"\n\"believe,\" \"expect,\" \"anticipate,\" \"intend,\" \"plan,\" \"estimate,\" and similar\nwords and the negative form thereof are used to identify forward-looking\nstatements. Forward-looking information may relate to management's future\noutlook and anticipated events or results and may include statements or\ninformation regarding the Company's results for the three and six months ended\nJune 30, 2026, business strategy and strategic goals, competitive conditions,\nresearch and development activities, projected costs and capital expenditures,\nresearch and clinical testing outcomes, taxes and plans and objectives of, or\ninvolving, Perimeter. Without limitation, information regarding the potential\nbenefits of Perimeter's S-Series and Claire™ OCT systems, and Perimeter's\nongoing clinical, regulatory, and commercialization activities, are\nforward-looking information. Forward-looking statements should not be read as\nguarantees of future performance or results, and will not necessarily be\naccurate indications of whether, or the times at or by which, any particular\nresult will be achieved. No assurance can be given that any events anticipated\nby the forward-looking information will transpire or occur. Forward-looking\ninformation is based on information available at the time and/or management's\ngood-faith belief with respect to future events and are subject to known or\nunknown risks, uncertainties, assumptions, and other unpredictable factors,\nmany of which are beyond Perimeter's control. Such forward-looking statements\nreflect Perimeter's current view with respect to future events, but are\ninherently subject to significant medical, scientific, business, economic,\ncompetitive, political, and social uncertainties and contingencies. In making\nforward-looking statements, Perimeter may make various material assumptions,\nincluding but not limited to (i) the accuracy of Perimeter's financial\nprojections; (ii) obtaining positive results from trials; (iii) obtaining\nnecessary regulatory approvals; and (iv) general business, market, and\neconomic conditions. Further risks, uncertainties and assumptions include, but\nare not limited to, those applicable to Perimeter and described in Perimeter's\nManagement Discussion and Analysis and Annual Information Form for the year\nended December 31, 2025, which are available on Perimeter's SEDAR+ profile at\nhttps://www.sedarplus.ca\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4756831-1&h=785710277&u=https%3A%2F%2Fwww.sedarplus.ca%2F&a=https%3A%2F%2Fwww.sedarplus.ca)\n, and could cause actual events or results to differ materially from those\nprojected in any forward-looking statements. Perimeter does not intend, nor\ndoes Perimeter undertake any obligation, to update or revise any\nforward-looking information contained in this news release to reflect\nsubsequent information, events, or circumstances or otherwise, except if\nrequired by applicable laws.\n\nFinancial Outlook\n\nThis press release contains a financial outlook within the meaning of\napplicable Canadian securities laws. The financial outlook has been prepared\nby management of the Company to provide an outlook for certain of the\nCompany's financial results for the three months ended June 30, 2026 and may\nnot be appropriate for any other purpose. The financial outlook has been\nprepared based on a number of assumptions including the assumptions discussed\nunder the heading \"Forward-Looking Statements\" herein. The actual results of\nthe Company's operations for any period will likely vary from the amounts set\nforth in these projections and such variations may be material. The Company\nand its management believe that the financial outlook has been prepared on a\nreasonable basis. However, because this information is highly subjective and\nsubject to numerous risks, including the risks discussed under the heading\n\"Forward-Looking Statements\" herein, it should not be relied on as necessarily\nindicative of future results.\n\nCONTACTS:\n\nStephen Kilmer\nInvestor Relations\nDirect: 647-872-4849\nEmail: skilmer@perimetermed.com (mailto:skilmer@perimetermed.com)\n\nAdrian Mendes\nChief Executive Officer\nToll-free: 888-988-7465 (PINK)\nEmail: investors@perimetermed.com (mailto:investors@perimetermed.com)\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/perimeter-announces-preliminary-second-quarter-2026-financial-results-302856831.html\n(https://www.prnewswire.com/news-releases/perimeter-announces-preliminary-second-quarter-2026-financial-results-302856831.html)\n\nSOURCE Perimeter Medical Imaging AI Inc.\n\n\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1414612/Perimeter-Medical-Imaging-AI-Inc-Perimeter-Announces-Preliminar.jpg?id=OA2900819\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPn9Y14j6a","title":"Perimeter Announces Preliminary Second Quarter 2026 Financial Results","author":"PR Newswire","ticker":"PINK","created":"2026-08-20T20:30:00.046Z","tickers":["PINK"],"exchange":"","article_body":"Perimeter Announces Preliminary Second Quarter 2026 Financial Results\n\nPR Newswire\n\nTORONTO and DALLAS, Aug. 20, 2026\n\nResults characterized by continued strong commercial momentum and improved\noperating performance\n\nConference call/webcast today at 5:00 pm ET\n\nTORONTO and DALLAS, Aug. 20, 2026 /PRNewswire/ -- Perimeter Medical Imaging\nAI, Inc. (TSXV: PINK) (OTCQX: PYNKF) (\"Perimeter\" or the \"Company\"), a\ncommercial-stage medical technology company, today reported preliminary\nfinancial results for its second quarter ended June 30, 2026, and provided a\ncorporate update. Unless specified otherwise, all amounts in this press\nrelease are expressed in U.S. dollars and are presented in accordance with\nInternational Financial Reporting Standards as issued by the International\nAccounting Standards Board.\n\n\"The commercial momentum that's been building over the past several quarters\nhas allowed us to execute our transition from selling our legacy FDA\n510(K)-cleared S-Series OCT to launching our next-generation, AI-enabled and\nFDA PMA-approved Claire™ OCT device from a position of strength,\" commented\nAdrian Mendes, Perimeter's Chief Executive Officer. \"And the results of that\nhave thus far exceeded our expectations, with the first two Claire placements\nalready made, and the first Claire commercial deployment by a major cancer\ncare center achieved. We look forward to updating all of our stakeholders as\nwe continue to grow.\"\n\nBusiness Highlights\n\nLegacy S-Series OCT to Commercial Launch of Claire OCT+AI\n\n * While the Company made final preparations ahead of the commercial launch of\nits flagship Claire OCT+AI device in the second quarter, recurring revenue\nfrom its legacy S-Series OCT grew 31% sequentially quarter-over quarter.\n * In April 2026, the Company formally unveiled Claire at the 27th Annual Meeting\nof the American Society of Breast Surgeons (ASBrS) in Seattle, WA.\n * Perimeter achieved the first two commercial placements of the Claire device\n– consisting of legacy replacements of Perimeter S-Series systems by two\ntop-tier hospitals – in May 2026, marking a critical step as the Company\nworks to establish its proprietary technology as a standard of care in\nbreast-conserving surgery.\n * In June 2026, Perimeter was selected to receive a $148,000 contribution from\nthe\nINOVAIT Pilot Fund\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4756831-1&h=1621375381&u=https%3A%2F%2Finovait.ca%2Ffunding%2F&a=INOVAIT+Pilot+Fund)\n\nto help build the next layer of Claire's infrastructure.\n * Last week, Perimeter announced that Intermountain Health, the largest\nnonprofit health system in the Mountain West region, had become the first\nhealth system in the U.S. to commercially deploy Claire for real-time margin\nassessment in breast-conserving surgeries.\nCorporate\n\n * In May 2026, Perimeter closed the final tranche of its previously announced\n\"best efforts\" offering, pursuant to the listed issuer financing exemption\n(Life Offering), bringing the total offering up to the maximum offering size\nof 21,489,000 units at a price of $0.35 per unit (C$7,521,150).\n * In June 2026, the Company closed the final tranche of its previously announced\nnon-brokered private placement (the \"Debenture Offering\") of C$1,000 principal\namount 3.59% convertible debentures of the Company (the \"Convertible\nDebentures\"). Under the first and second tranches of Debenture Offering, the\nCompany issued an aggregate of C$6,040,000 principal amount of Convertible\nDebentures.\nSummary Preliminary Second Quarter 2026 Financial Results(1)\n\nRevenue was approximately $503,000 for the second quarter of 2026, with the\nfull amount coming from recurring revenue, which consisted of the sale of\nS-Series consumables and system leases, as well as from preventative\nmaintenance services and the sale of ESP warranty programs. Second quarter\n2026 revenues were essentially unchanged from $506,000 in Q1-2025, and up 31%\nfrom approximately $385,000 in Q1-2026.\n\nOperating expenses for the three months ended June 30, 2026 were approximately\n$3.1 million, down 28% from $4.3 million in the same period in 2025.\n\nSecond quarter 2026 net loss was approximately $2.6 million, or $0.02 per\ncommon share, a 33% improvement compared to approximately $3.9 million, or\n$0.04 per common share, in the three months ended June 30, 2025.\n\nCash used in operating activities in the six months ended June 30, 2026, was\napproximately $5.1 million, a 23% decrease from the comparable period in 2025.\n\nAs of June 30, 2026, cash was approximately $6.4 million.\n\n(1) These preliminary financial results are subject to customary financial\nstatement procedures by the Company and its auditors. Actual results could be\naffected by subsequent events or determinations. While the Company believes\nthere is a reasonable basis for these preliminary financial results, the\nresults involve known and unknown risks and uncertainties that may cause\nactual results to differ materially. Preliminary fiscal results represent\nforward-looking information. See \"Forward-Looking Statements\" and \"Financial\nOutlook\".\n\nConference Call\n\nThe Company will host a conference call and live audio webcast today at 5:00\npm Eastern Time to discuss its second quarter 2026 results and provide a\ncorporate update. To participate in the call, please dial 1-800-717-1738 or\n1-646-307-1865. The conference call will also be broadcast live online through\na listen-only webcast\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4756831-1&h=2503541369&u=https%3A%2F%2Fviavid.webcasts.com%2Fstarthere.jsp%3Fei%3D1771430%26tp_key%3D1168c24061&a=listen-only+webcast)\n, which will be posted on the Investors section of the Company's website\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4756831-1&h=3745814786&u=https%3A%2F%2Fir.perimetermed.com%2F&a=Company%27s+website)\n and archived for approximately 90 days.\n\nAbout Perimeter Medical Imaging AI, Inc.\n\nBased in Toronto, Canada and Dallas, Texas, Perimeter Medical Imaging AI\n(TSX-V: PINK) (OTCQX: PYNKF) is a medical technology company driven to\ntransform cancer surgery with ultra-high-resolution, real-time, advanced\nimaging tools to address areas of high unmet medical need. Claire™, recently\napproved by the U.S. Food and Drug Administration (FDA), is our\nnext-generation AI-enabled device. The Company's ticker symbol \"PINK\" is a\nreference to the pink ribbons used during Breast Cancer Awareness Month.\n\nIndications for Use: The Claire OCT System is an adjunctive three-dimensional\nimaging tool which provides volumetric cross-sectional, real-time depth\nvisualization, coupled with an artificial intelligence computer-aided\ndetection algorithm which identifies and marks focal areas suspicious for\nbreast cancer. It is used concurrently with physician interpretation of the\nimages. The Claire OCT System is intended for use in conjunction with other\nstandard methods for evaluation of the margins of excised lumpectomy tissue\nduring surgical procedures in patients with a biopsy-confirmed diagnosis of\nbreast cancer.\n\nThe Claire OCT System should not be used to replace standard tissue\nhistopathology assessment and should not be used for diagnosis. The device is\nnot intended for use in any of the following individuals: under the age of 18,\nmale, have metastatic cancer (Stage IV), have lobular carcinoma as their\nprimary diagnosis, have had previous ipsilateral breast surgery for benign or\nmalignant disease within two years (including implants and breast\naugmentation), patients with multi-centric disease (histologically diagnosed\ncancer in two different quadrants of the breast), unless resected in a single\nspecimen, patients with bilateral disease (diagnosed cancer in both breasts),\npatients who are currently lactating, patients who are currently pregnant, or\nconcurrent use in surgeries with cryo-assisted localization. Refer to\nprescriber labeling for full safety information.\n\nNeither the TSX Venture Exchange nor its Regulation Services Provider (as that\nterm is defined in policies of the TSX Venture Exchange) accepts\nresponsibility for the adequacy or accuracy of this release.\n\nForward-Looking Statements\n\nThis news release contains statements that constitute \"forward-looking\ninformation\" within the meaning of applicable Canadian securities legislation.\nIn this news release, words such as \"may,\" \"would,\" \"could,\" \"will,\" \"likely,\"\n\"believe,\" \"expect,\" \"anticipate,\" \"intend,\" \"plan,\" \"estimate,\" and similar\nwords and the negative form thereof are used to identify forward-looking\nstatements. Forward-looking information may relate to management's future\noutlook and anticipated events or results and may include statements or\ninformation regarding the Company's results for the three and six months ended\nJune 30, 2026, business strategy and strategic goals, competitive conditions,\nresearch and development activities, projected costs and capital expenditures,\nresearch and clinical testing outcomes, taxes and plans and objectives of, or\ninvolving, Perimeter. Without limitation, information regarding the potential\nbenefits of Perimeter's S-Series and Claire™ OCT systems, and Perimeter's\nongoing clinical, regulatory, and commercialization activities, are\nforward-looking information. Forward-looking statements should not be read as\nguarantees of future performance or results, and will not necessarily be\naccurate indications of whether, or the times at or by which, any particular\nresult will be achieved. No assurance can be given that any events anticipated\nby the forward-looking information will transpire or occur. Forward-looking\ninformation is based on information available at the time and/or management's\ngood-faith belief with respect to future events and are subject to known or\nunknown risks, uncertainties, assumptions, and other unpredictable factors,\nmany of which are beyond Perimeter's control. Such forward-looking statements\nreflect Perimeter's current view with respect to future events, but are\ninherently subject to significant medical, scientific, business, economic,\ncompetitive, political, and social uncertainties and contingencies. In making\nforward-looking statements, Perimeter may make various material assumptions,\nincluding but not limited to (i) the accuracy of Perimeter's financial\nprojections; (ii) obtaining positive results from trials; (iii) obtaining\nnecessary regulatory approvals; and (iv) general business, market, and\neconomic conditions. Further risks, uncertainties and assumptions include, but\nare not limited to, those applicable to Perimeter and described in Perimeter's\nManagement Discussion and Analysis and Annual Information Form for the year\nended December 31, 2025, which are available on Perimeter's SEDAR+ profile at\nhttps://www.sedarplus.ca\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4756831-1&h=785710277&u=https%3A%2F%2Fwww.sedarplus.ca%2F&a=https%3A%2F%2Fwww.sedarplus.ca)\n, and could cause actual events or results to differ materially from those\nprojected in any forward-looking statements. Perimeter does not intend, nor\ndoes Perimeter undertake any obligation, to update or revise any\nforward-looking information contained in this news release to reflect\nsubsequent information, events, or circumstances or otherwise, except if\nrequired by applicable laws.\n\nFinancial Outlook\n\nThis press release contains a financial outlook within the meaning of\napplicable Canadian securities laws. The financial outlook has been prepared\nby management of the Company to provide an outlook for certain of the\nCompany's financial results for the three months ended June 30, 2026 and may\nnot be appropriate for any other purpose. The financial outlook has been\nprepared based on a number of assumptions including the assumptions discussed\nunder the heading \"Forward-Looking Statements\" herein. The actual results of\nthe Company's operations for any period will likely vary from the amounts set\nforth in these projections and such variations may be material. The Company\nand its management believe that the financial outlook has been prepared on a\nreasonable basis. However, because this information is highly subjective and\nsubject to numerous risks, including the risks discussed under the heading\n\"Forward-Looking Statements\" herein, it should not be relied on as necessarily\nindicative of future results.\n\nCONTACTS:\n\nStephen Kilmer\nInvestor Relations\nDirect: 647-872-4849\nEmail: skilmer@perimetermed.com (mailto:skilmer@perimetermed.com)\n\nAdrian Mendes\nChief Executive Officer\nToll-free: 888-988-7465 (PINK)\nEmail: investors@perimetermed.com (mailto:investors@perimetermed.com)\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/perimeter-announces-preliminary-second-quarter-2026-financial-results-302856831.html\n(https://www.prnewswire.com/news-releases/perimeter-announces-preliminary-second-quarter-2026-financial-results-302856831.html)\n\nSOURCE Perimeter Medical Imaging AI Inc.\n\n\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1414612/Perimeter-Medical-Imaging-AI-Inc-Perimeter-Announces-Preliminar.jpg?id=OA2900819\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-08-20T20:30:00.111343312Z","server_sent_at_ms":1787257800111},"received_at":"2026-08-20T20:30:00.162Z","source_url":"https://www.prnewswire.com/news-releases/perimeter-announces-preliminary-second-quarter-2026-financial-results-302856831.html"},"analysis":{"id":"113453","press_release_id":"124483","analysis_json":{"industry":{"label":"Health Care Equipment & Supplies","sector":"Health Care"},"redFlags":["Cash balance of $6.4 million versus 6-month operating cash burn of $5.1 million implies limited runway without additional capital.","Revenue remains low at $503,000 despite sequential growth."],"eventType":"earnings","narrative":"Perimeter reported Q2 2026 revenue of $503,000, up 31% sequentially, while operating expenses fell 28% year-over-year to $3.1 million, driving a 33% improvement in net loss to $2.6 million.\n\nCommercial execution accelerated with the first placements of the Claire OCT device at top-tier hospitals and the first commercial deployment by Intermountain Health, signaling successful transition to the AI-enabled platform.\n\nThe company solidified its balance sheet by closing a final tranche of a $0.35 per unit offering and issuing C$6.04 million in convertible debentures, ending the quarter with $6.4 million in cash.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"Burn rate shrinks and Claire device gains traction, but cash runway remains tight."},"keyFigures":{"revenue":503000,"customDimensions":{"net_loss":"$2.6 million","cash_balance":"$6.4 million","offering_price":"$0.35","offering_units":21489000,"operating_expenses":"$3.1 million","sequential_revenue_growth":"31%","convertible_debentures_total":"C$6,040,000"}},"quotedText":"The commercial momentum that's been building over the past several quarters has allowed us to execute our transition from selling our legacy FDA 510(K)-cleared S-Series OCT to launching our next-generation, AI-enabled and FDA PMA-approved Claire™ OCT device from a position of strength","namedEntities":{"people":[{"name":"Adrian Mendes","role":"Chief Executive Officer"},{"name":"Stephen Kilmer","role":"Investor Relations"}],"products":["S-Series OCT","Claire OCT+AI","Claire OCT System"],"companies":[{"name":"Perimeter Medical Imaging AI, Inc.","ticker":"PINK"},{"name":"Intermountain Health","relationship":"customer"},{"name":"INOVAIT Pilot Fund","relationship":"funding body"}],"dollarAmounts":[{"amount":"$503,000","context":"Q2 2026 revenue"},{"amount":"$3.1 million","context":"Q2 2026 operating expenses"},{"amount":"$2.6 million","context":"Q2 2026 net loss"},{"amount":"$6.4 million","context":"cash as of June 30, 2026"},{"amount":"$0.35","context":"offering price per unit"},{"amount":"C$7,521,150","context":"total offering size"},{"amount":"C$6,040,000","context":"aggregate principal amount of Convertible Debentures"},{"amount":"$148,000","context":"INOVAIT Pilot Fund contribution"}]},"materialImpact":{"score":4,"reasoning":"Revenue grew 31% sequentially while operating expenses dropped 28% year-over-year, significantly narrowing the net loss. First commercial placements of the flagship Claire device were achieved, validating the commercialization strategy."},"tickerRelevance":{"others":[{"ticker":"PYNKF","relevance":"OTCQX listing"}],"primary":"PINK"},"globalImportance":18,"audienceRelevance":22,"eventTypeSecondary":["product_launch","offering","debt_offering"],"importanceComponents":{"tickerTier":"micro-cap","eventGravity":"small-cap-earnings-commercial-milestone","sectorWeight":"health-tech"}},"event_type":"earnings","event_type_secondary":["product_launch","offering","debt_offering"],"sentiment":"bullish","material_impact_score":4,"narrative":"Perimeter reported Q2 2026 revenue of $503,000, up 31% sequentially, while operating expenses fell 28% year-over-year to $3.1 million, driving a 33% improvement in net loss to $2.6 million.\n\nCommercial execution accelerated with the first placements of the Claire OCT device at top-tier hospitals and the first commercial deployment by Intermountain Health, signaling successful transition to the AI-enabled platform.\n\nThe company solidified its balance sheet by closing a final tranche of a $0.35 per unit offering and issuing C$6.04 million in convertible debentures, ending the quarter with $6.4 million in cash.","key_figures":{"revenue":503000,"customDimensions":{"net_loss":"$2.6 million","cash_balance":"$6.4 million","offering_price":"$0.35","offering_units":21489000,"operating_expenses":"$3.1 million","sequential_revenue_growth":"31%","convertible_debentures_total":"C$6,040,000"}},"named_entities":{"people":[{"name":"Adrian Mendes","role":"Chief Executive Officer"},{"name":"Stephen Kilmer","role":"Investor Relations"}],"products":["S-Series OCT","Claire OCT+AI","Claire OCT System"],"companies":[{"name":"Perimeter Medical Imaging AI, Inc.","ticker":"PINK"},{"name":"Intermountain Health","relationship":"customer"},{"name":"INOVAIT Pilot Fund","relationship":"funding body"}],"dollarAmounts":[{"amount":"$503,000","context":"Q2 2026 revenue"},{"amount":"$3.1 million","context":"Q2 2026 operating expenses"},{"amount":"$2.6 million","context":"Q2 2026 net loss"},{"amount":"$6.4 million","context":"cash as of June 30, 2026"},{"amount":"$0.35","context":"offering price per unit"},{"amount":"C$7,521,150","context":"total offering size"},{"amount":"C$6,040,000","context":"aggregate principal amount of Convertible Debentures"},{"amount":"$148,000","context":"INOVAIT Pilot Fund contribution"}]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-08-20T20:55:50.598Z","global_importance":18,"audience_relevance":22,"importance_components":{"tickerTier":"micro-cap","eventGravity":"small-cap-earnings-commercial-milestone","sectorWeight":"health-tech"}},"durationMs":194732,"modelName":"glm-4.7"}}